#stance=stance2
#originalStanceText=No
#originalTopic=Debate:_Single-payer_universal_health_care
Allowing for pooling of resources to force drugs to lower prices will reduce overall innovation.  Reducing profit, reduces motive and the money necessary to get a drug through FDA trials.  Without profit motive, drug companies will naturally move away from the rare and complex, yet fatal, diseases if they only affect a small percentage of people.  Without the ability to set the price, their resources will naturally be moved almost exclusively into benign treatments which will have a larger percentage of the population as potential users.
